{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T21:18:44Z","timestamp":1792703924477,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.euo.2025.06.003","type":"journal-article","created":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T15:08:02Z","timestamp":1754406482000},"page":"1174-1181","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["The Evolving Landscape of Systemic Immunotherapy for Bacillus Calmette-Gu\u00e9rin\u2013na\u00efve High-risk Non\u2013muscle-invasive Bladder Cancer: At the Edge of a Tsunami?"],"prefix":"10.1016","volume":"8","author":[{"given":"Pierre-Etienne","family":"Gabriel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Roumigui\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gautier","family":"Marcq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Allory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Sophie","family":"Bajeot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Leon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Prad\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2025.06.003_b0005","unstructured":"Cancer Today. http:\/\/gco.iarc.fr\/today\/home."},{"key":"10.1016\/j.euo.2025.06.003_b0010","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.eururo.2015.06.045","article-title":"EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Gu\u00e9rin","volume":"69","author":"Cambier","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.003_b0015","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014a summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.003_b0020","first-page":"423","article-title":"Failure of bacillus Calmette-Gu\u00e9rin therapy in non-muscle-invasive bladder cancer: definition and treatment options","volume":"69","author":"Gual Frau","year":"2016","journal-title":"Arch Esp Urol"},{"key":"10.1016\/j.euo.2025.06.003_b0025","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"Balar","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.06.003_b0030","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.eururo.2023.08.004","article-title":"Phase 2 trial of atezolizumab in bacillus Calmette-Gu\u00e9rin-unresponsive high-risk non-muscle-invasive bladder cancer: SWOG S1605","volume":"84","author":"Black","year":"2023","journal-title":"Eur Urol"},{"issue":"6_suppl","key":"10.1016\/j.euo.2025.06.003_b0035","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.6_suppl.TPS593","article-title":"SunRISe-1: phase 2b study of TAR-200 plus cetrelimab, TAR-200 alone, or cetrelimab alone in participants with high-risk nonmuscle-invasive bladder cancer unresponsive to bacillus Calmette-Gu\u00e9rin who are ineligible for or decline radical cystectomy","volume":"40","author":"Van Der Heijden","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.003_b0040","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.06.003_b0045","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.euo.2025.06.003_b0050","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.003_b0055","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(21)00004-8","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2025.06.003_b0060","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.003_b0065","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1056\/NEJMoa2309863","article-title":"Nivolumab plus gemcitabine-cisplatin in advanced urothelial carcinoma","volume":"389","author":"van der Heijden","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.003_b0070","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.003_b0075","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2025.06.003_b0080","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2025.06.003_b0085","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.euo.2025.06.003_b0090","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014;507:315\u201322.","DOI":"10.1038\/nature12965"},{"key":"10.1016\/j.euo.2025.06.003_b0095","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","article-title":"Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with bacillus Calmette-Guerin","volume":"9","author":"Hashizume","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.euo.2025.06.003_b0100","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1245\/s10434-018-6498-2","article-title":"Clinical role of programmed cell death-1 expression in patients with non-muscle-invasive bladder cancer recurring after initial bacillus Calmette-Gu\u00e9rin therapy","volume":"25","author":"Fukumoto","year":"2018","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.euo.2025.06.003_b0105","first-page":"466","article-title":"Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease","volume":"15","author":"Yu","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.euo.2025.06.003_b0110","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41585-021-00481-1","article-title":"100 Years of bacillus Calmette-Gu\u00e9rin immunotherapy: from cattle to COVID-19","volume":"18","author":"Lobo","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2025.06.003_b0115","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41585-020-0346-4","article-title":"Trained immunity as a molecular mechanism for BCG immunotherapy in bladder cancer","volume":"17","author":"van Puffelen","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.euo.2025.06.003_b0120","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.eururo.2023.01.017","article-title":"A phase 1 trial of durvalumab in combination with bacillus Calmette-Guerin (BCG) or external beam radiation therapy in patients with BCG-unresponsive non-muscle-invasive bladder cancer: the Hoosier Cancer Research Network GU16-243 ADAPT-BLADDER study","volume":"83","author":"Hahn","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.003_b0125","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.euo.2023.01.013","article-title":"A phase 1b\/2 study of atezolizumab with or without bacille Calmette-Gu\u00e9rin in patients with high-risk non-muscle-invasive bladder cancer","volume":"6","author":"Inman","year":"2023","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.euo.2025.06.003_b0130","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1158\/1535-7163.MCT-20-0093","article-title":"Pharmacologic properties and preclinical activity of sasanlimab, a high-affinity engineered anti-human PD-1 antibody","volume":"19","author":"Al-Khami","year":"2020","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.euo.2025.06.003_b0135","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamaoncol.2019.0836","article-title":"Assessment of subcutaneous vs intravenous administration of anti-PD-1 antibody PF-06801591 in patients with advanced solid tumors: a phase 1 dose-escalation trial","volume":"5","author":"Johnson","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.euo.2025.06.003_b0140","doi-asserted-by":"crossref","first-page":"S721","DOI":"10.1016\/j.annonc.2020.08.1175","article-title":"1055P Updated results of subcutaneous (SC) anti-programmed cell death 1 (PD-1) receptor antibody PF-06801591 for locally advanced or metastatic non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC)","volume":"31","author":"Cho","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2025.06.003_b0145","unstructured":"AUA. Sasanlimab in combination with BCG improves event-free survival vs BCG as standard of care in high-risk non-muscle-invasive bladder cancer: phase 3 CREST study results; 2025. https:\/\/www.urotoday.com\/conference-highlights\/aua-2025\/aua-2025-bladder-cancer\/159968-aua-2025-sasanlimab-in-combination-with-bacillus-calmette-guerin-improves-event-free-survival-versus-bacillus-calmette-guerin-as-standard-of-care-in-high-risk-non-muscle-invasive-bladder-cancer-phase-3-crest-study-results.html."},{"key":"10.1016\/j.euo.2025.06.003_b0150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.eururo.2021.03.024","article-title":"Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma: a long-term overall survival and safety update from the phase 3 IMvigor211 clinical trial","volume":"80","author":"van der Heijden","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.003_b0155","doi-asserted-by":"crossref","first-page":"3875","DOI":"10.1158\/1078-0432.CCR-23-0354","article-title":"A phase II study of durvalumab for bacillus Calmette-Guerin (BCG) unresponsive urothelial carcinoma in situ of the bladder","volume":"29","author":"Li","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2025.06.003_b0160","unstructured":"Center for Drug Evaluation and Research, FDA. FDA approves pembrolizumab for BCG-unresponsive, high-risk non-muscle invasive bladder cancer. FDA; 8 Sept 2024. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-bcg-unresponsive-high-risk-non-muscle-invasive-bladder-cancer."},{"key":"10.1016\/j.euo.2025.06.003_b0165","doi-asserted-by":"crossref","first-page":"3807","DOI":"10.1007\/s00345-021-03716-3","article-title":"Phase I trial of intravesical bacillus Calmette-Gu\u00e9rin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous bacillus Calmette-Gu\u00e9rin treatment","volume":"39","author":"Alanee","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.euo.2025.06.003_b0170","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.eururo.2020.04.066","volume":"78","author":"Grimm","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.003_b0175","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","article-title":"Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance","volume":"63","author":"Oddens","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.003_b0180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","volume":"65","author":"Brausi","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2025.06.003_b0185","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/S0302-2838(03)00357-9","article-title":"EORTC Genito-Urinary Tract Cancer Group. Maintenance bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group phase III trial","volume":"44","author":"van der Meijden","year":"2003","journal-title":"Eur Urol"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931125001749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:27:19Z","timestamp":1758079639000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931125001749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2588931125001749"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2025.06.003","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Evolving Landscape of Systemic Immunotherapy for Bacillus Calmette-Gu\u00e9rin\u2013na\u00efve High-risk Non\u2013muscle-invasive Bladder Cancer: At the Edge of a Tsunami?","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2025.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}